DNAG - $$ Receives Notice of Allowance for Patent $$ - 500 Beiträge pro Seite
eröffnet am 20.04.06 14:49:54 von
neuester Beitrag 20.04.06 21:46:30 von
neuester Beitrag 20.04.06 21:46:30 von
Beiträge: 7
ID: 1.054.966
ID: 1.054.966
Aufrufe heute: 0
Gesamt: 796
Gesamt: 796
Aktive User: 0
ISIN: US23324Q2021 · WKN: A0ETWM · Symbol: DNAG
0,0000
USD
0,00 %
0,0000 USD
Letzter Kurs 22.05.24 Nasdaq OTC
Neuigkeiten
TitelBeiträge |
---|
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
0,8000 | +2.566,67 | |
3,3000 | +44,74 | |
1,2200 | +31,76 | |
1,2450 | +29,69 | |
7,7600 | +29,33 |
Wertpapier | Kurs | Perf. % |
---|---|---|
2,7900 | -24,80 | |
1,0100 | -26,81 | |
9,5300 | -34,00 | |
1,2400 | -34,39 | |
1,0950 | -34,43 |
heute wird die Post abgehen....
jetzt noch schnell die 45min vorsprung nutzen und hier unter 0,02€ rein...
liebe Grüße und hier die news:
DNAPrint Genomics Receives Notice of Allowance for Patent for Identifying Links Between Gene Sequences and Medical Traits
Thursday April 20, 7:00 am ET
Sophisticated Technology Utilized by Company\'s DNAPrint Pharmaceuticals Subsidiary
SARASOTA, FL--(MARKET WIRE)--Apr 20, 2006 -- DNAPrint Genomics, Inc. (OTC BBNAG.OB - News) today announced that the Company has received a Notice of Allowance from the U.S. Patent and Tradmark Office for a patent application, Methods for the Identification of Genetic Features for Complex Genetics Classifiers. The patent protects the Company\'s methods for identifying links between gene sequences and phenotypes (physical or medical traits).
ADVERTISEMENT
"Gene sequences are highly polymorphic in the population, which means that they come in various forms or \'flavors,\'" stated DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis. "Polymorphism is usually measured at the level of the single nucleotide polymorphism (SNP) but our technology measures at the level of the haplotype (strings of SNPs), which provides researchers considerably more information. The methods covered in the patent allow for an efficient and powerful means for identifying haplotype."
The recent patent provides legal protection for DNAPrint\'s status as one of a very few companies currently capable of performing objective, assumption-free haplotype analyses. DNAPrint is also the only company currently using Ancestry Informative Markers (AIMs) and has patents pending in this area as well. Because of limitations with traditional genome screening methods and the complex genetic characteristics of modern populations, AIMS are integral to the development of DNA tests for the inference of genetic ancestry based on phenotypes, including identifying certain physical characteristics, or an individual\'s predisposition to respond to certain drugs.
"The Company is committed to developing a new class of drugs, called \'theranostics,\' which are test+drug combinations designed to help ensure that patients receive the appropriate medicine and proper dosage based on their genetic constitution. The application of theranostics is also designed to increase efficacy and reduce side-effects," said DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D. "Our sophisticated genetics technology is playing a key role in the research and development of potential new drugs."
"This patent cuts across a wide audience of developers from drug companies to people working on technology in the forensics and consumer areas," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We plan to vigorously utilize and practice our patents and we will be reviewing the fields of genetic testing, drug development, forensic sciences and consumer products with our patent counsel to determine potential areas of development. We want to ensure that we extract the greatest economic value out of this patent for our shareholders and investors."
DNAPrint Genomics currently holds two patents and has several others pending or in the hands of patent counsel.
jetzt noch schnell die 45min vorsprung nutzen und hier unter 0,02€ rein...
liebe Grüße und hier die news:
DNAPrint Genomics Receives Notice of Allowance for Patent for Identifying Links Between Gene Sequences and Medical Traits
Thursday April 20, 7:00 am ET
Sophisticated Technology Utilized by Company\'s DNAPrint Pharmaceuticals Subsidiary
SARASOTA, FL--(MARKET WIRE)--Apr 20, 2006 -- DNAPrint Genomics, Inc. (OTC BBNAG.OB - News) today announced that the Company has received a Notice of Allowance from the U.S. Patent and Tradmark Office for a patent application, Methods for the Identification of Genetic Features for Complex Genetics Classifiers. The patent protects the Company\'s methods for identifying links between gene sequences and phenotypes (physical or medical traits).
ADVERTISEMENT
"Gene sequences are highly polymorphic in the population, which means that they come in various forms or \'flavors,\'" stated DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis. "Polymorphism is usually measured at the level of the single nucleotide polymorphism (SNP) but our technology measures at the level of the haplotype (strings of SNPs), which provides researchers considerably more information. The methods covered in the patent allow for an efficient and powerful means for identifying haplotype."
The recent patent provides legal protection for DNAPrint\'s status as one of a very few companies currently capable of performing objective, assumption-free haplotype analyses. DNAPrint is also the only company currently using Ancestry Informative Markers (AIMs) and has patents pending in this area as well. Because of limitations with traditional genome screening methods and the complex genetic characteristics of modern populations, AIMS are integral to the development of DNA tests for the inference of genetic ancestry based on phenotypes, including identifying certain physical characteristics, or an individual\'s predisposition to respond to certain drugs.
"The Company is committed to developing a new class of drugs, called \'theranostics,\' which are test+drug combinations designed to help ensure that patients receive the appropriate medicine and proper dosage based on their genetic constitution. The application of theranostics is also designed to increase efficacy and reduce side-effects," said DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D. "Our sophisticated genetics technology is playing a key role in the research and development of potential new drugs."
"This patent cuts across a wide audience of developers from drug companies to people working on technology in the forensics and consumer areas," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We plan to vigorously utilize and practice our patents and we will be reviewing the fields of genetic testing, drug development, forensic sciences and consumer products with our patent counsel to determine potential areas of development. We want to ensure that we extract the greatest economic value out of this patent for our shareholders and investors."
DNAPrint Genomics currently holds two patents and has several others pending or in the hands of patent counsel.
und schon kommen die ersten direkten Empfehlungen:
Market Pulse Announces Its AM Stock Picks for Thursday, April 20, 2006: FNSR, DNAG, EBAY, SATC
ATLANTA, April 20, 2006 (PRIMEZONE) -- Market Pulse is pleased to announce the following stock recommendations. Bernard Schmitt of Market Pulse states, "These notable stocks should be watched because they look great from a fundamental and technical perspective." Bernard possesses many years of experience in the financial industry recommending and evaluating stocks. He rates them as follows:
Finisar Corp. (Nasdaq: FNSR): Market Outperform
DNAPrint Genomics Inc. (OTCBB: DNAG): Attractive
eBay Inc. (Nasdaq: EBAY): Bearish
SatCon Technology Corp. (Nasdaq: SATC): Attractive
Recommendation Meanings
These recommendations are investment opinions of Market-Pulse.com and reflect the stock's potential to move over the next one to four weeks of trading. This analysis is done from a technical and fundamental perspective.
After The Bell Market Commentary
According to Bernard Schmitt, "On Wednesday, higher gasoline prices lifted the Consumer Price Index 0.4% in March, well above the 0.1% increase in February. Excluding food and energy, core inflation rose 0.3%, the largest gain in a year. Light sweet crude for May delivery climbed as high as $72.40 a barrel, before settling at $72.17. Gold prices rose toward $650 an ounce, a 25-year high. Upbeat corporate earnings lifted the markets to a modestly higher close. The Dow Jones industrial average gained 10.00, or 0.09 percent, to 11,278.77. The Nasdaq composite index rose 14.74, or 0.63 percent, to 2,370.88, a five-year high. The Standard & Poor's 500 index adding 2.28, or 0.17 percent, to 1,309.93. The Russell 2000 index rose 8.61, or 1.12 percent, to 778.42."
About Market-Pulse.com
Grüße
Svenja
Market Pulse Announces Its AM Stock Picks for Thursday, April 20, 2006: FNSR, DNAG, EBAY, SATC
ATLANTA, April 20, 2006 (PRIMEZONE) -- Market Pulse is pleased to announce the following stock recommendations. Bernard Schmitt of Market Pulse states, "These notable stocks should be watched because they look great from a fundamental and technical perspective." Bernard possesses many years of experience in the financial industry recommending and evaluating stocks. He rates them as follows:
Finisar Corp. (Nasdaq: FNSR): Market Outperform
DNAPrint Genomics Inc. (OTCBB: DNAG): Attractive
eBay Inc. (Nasdaq: EBAY): Bearish
SatCon Technology Corp. (Nasdaq: SATC): Attractive
Recommendation Meanings
These recommendations are investment opinions of Market-Pulse.com and reflect the stock's potential to move over the next one to four weeks of trading. This analysis is done from a technical and fundamental perspective.
After The Bell Market Commentary
According to Bernard Schmitt, "On Wednesday, higher gasoline prices lifted the Consumer Price Index 0.4% in March, well above the 0.1% increase in February. Excluding food and energy, core inflation rose 0.3%, the largest gain in a year. Light sweet crude for May delivery climbed as high as $72.40 a barrel, before settling at $72.17. Gold prices rose toward $650 an ounce, a 25-year high. Upbeat corporate earnings lifted the markets to a modestly higher close. The Dow Jones industrial average gained 10.00, or 0.09 percent, to 11,278.77. The Nasdaq composite index rose 14.74, or 0.63 percent, to 2,370.88, a five-year high. The Standard & Poor's 500 index adding 2.28, or 0.17 percent, to 1,309.93. The Russell 2000 index rose 8.61, or 1.12 percent, to 778.42."
About Market-Pulse.com
Grüße
Svenja
danke für den tipp svenja !
RT 0,019€
USA:
Time Ex Price Change Volume
10:00:56 Q 0.023 +0.0034 100,000
10:00:56 Q 0.023 +0.0034 100,000
09:59:32 Q 0.024 +0.0044 69,500
09:58:29 Q 0.024 +0.0044 75,000
09:58:19 Q 0.024 +0.0044 75,000
09:58:09 Q 0.024 +0.0044 5,000
09:57:29 Q 0.024 +0.0044 5,000
09:56:39 Q 0.023 +0.0034 20,000
09:55:27 Q 0.023 +0.0034 200,000
09:54:37 Q 0.023 +0.0034 48,000
ich denke so kann es weiter gehen..
grüße
svenja
USA:
Time Ex Price Change Volume
10:00:56 Q 0.023 +0.0034 100,000
10:00:56 Q 0.023 +0.0034 100,000
09:59:32 Q 0.024 +0.0044 69,500
09:58:29 Q 0.024 +0.0044 75,000
09:58:19 Q 0.024 +0.0044 75,000
09:58:09 Q 0.024 +0.0044 5,000
09:57:29 Q 0.024 +0.0044 5,000
09:56:39 Q 0.023 +0.0034 20,000
09:55:27 Q 0.023 +0.0034 200,000
09:54:37 Q 0.023 +0.0034 48,000
ich denke so kann es weiter gehen..
grüße
svenja
We want to ensure that we extract the greatest economic value out of this patent for our shareholders and investors."
Gefällt mir gut der letzte Satz.
Gefällt mir gut der letzte Satz.
Bin mit von der Partie
Je später der Abend umso tiefer der Kurs. War wohl wie schon so oft nur heiße Luft.
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
+0,20 | |
0,00 | |
-0,94 | |
+2,52 | |
+1,63 | |
-0,37 | |
-0,69 | |
+2,65 | |
-0,63 | |
-1,10 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
59 | ||
40 | ||
20 | ||
19 | ||
19 | ||
17 | ||
17 | ||
16 | ||
15 | ||
14 |